Bo Anders Ljungqvist

LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark.

The Leo Group provides software solutions. The company develops custom applications using component technology to deliver solutions tailored to client needs. It provides applications using bar-code technology, multi-media and database integration, complex printer collation, and MS Office software automation. The company was founded in 1983 and is headquartered in Hershey, PA.

Invest AD Asset Management PJSC (Invest AD) is the sovereign wealth manager of government-owned Abu Dhabi Investment Council. The firm was founded in 1977 and is headquartered in Abu Dhabi. Invest AD provides asset management services to international high-net worth individuals and institutions.

Coegin Pharma AS provides therapeutics that addresses inflammatory diseases. The company was founded by Berit Johansen on January 3, 2005 and is headquartered in Trondheim, Norway.

Ground Control Labs AS is a holding company that makes digital products. It develops the mobile and laptop social software Moot for various platforms. It provides social networking software for desktop computers and handheld devices. The company was founded by André Mlonyeni, Sigrid Bygdås, and Tore Urnes in 2006 and is headquartered in Oslo, Norway.

RhoVac AB opertaes as biotechnology company that engages in the research and development of immunotherapy. The firm develops therapeutic cancer vaccines. Its main focus is the development of a drug with the potential to prevent or limit the metastasis of metastatic cancers. The company was founded by Bo Anders Ljungqvist, Per Thor Straten, and Mads Hald Andersen in November 2015 and is headquartered in Lund, Sweden.

Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019.